Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Ferlay, 2010

Gallo, 2006, Updates on esophageal and gastric cancers, World J Gastroenterol, 12, 3237, 10.3748/wjg.v12.i20.3237

Gunderson, 2002, Gastric cancer—patterns of relapse after surgical resection, Semin Radiat Oncol, 12, 150, 10.1053/srao.2002.30817

Park, 2008, Current approaches to gastric cancer in Korea, Gastrointest Cancer Res, 2, 137

Cuschieri, 1999, Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial, Br J Cancer, 79, 1522, 10.1038/sj.bjc.6690243

Bonenkamp, 1999, Extended lymph-node dissection for gastric cancer, N Engl J Med, 340, 908, 10.1056/NEJM199903253401202

Songun, 2010, Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial, Lancet Oncol, 11, 439, 10.1016/S1470-2045(10)70070-X

Wu, 2006, Nodal dissection for patients with gastric cancer: a randomised controlled trial, Lancet Oncol, 7, 309, 10.1016/S1470-2045(06)70623-4

Okines, 2010, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v50, 10.1093/annonc/mdq164

Paoletti, 2010, Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, JAMA, 303, 1729, 10.1001/jama.2010.534

Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N Engl J Med, 357, 1810, 10.1056/NEJMoa072252

Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 725, 10.1056/NEJMoa010187

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531

Ohtsu, 2005, Overview of adjuvant therapy for resected gastric cancer: differences in Japan and the United States, Semin Oncol, 32, S101, 10.1053/j.seminoncol.2005.06.001

Ohtsu, 2006, Disparities in gastric cancer chemotherapy between the East and West, J Clin Oncol, 24, 2188, 10.1200/JCO.2006.05.9758

Sasako, 2011, Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer, J Clin Oncol, 29, 4387, 10.1200/JCO.2011.36.5908

Jatoi, 2006, Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group, Ann Oncol, 17, 29, 10.1093/annonc/mdj063

Liu, 2008, Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer, Anticancer Drugs, 19, 825, 10.1097/CAD.0b013e32830c457e

Luo, 2010, Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer, Chemotherapy, 56, 94, 10.1159/000305256

Park, 2008, Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer, Cancer Chemother Pharmacol, 61, 623, 10.1007/s00280-007-0515-7

2003

Lan, 1983, Discrete sequential boundaries for clinical trials, Biometrika, 70, 659, 10.2307/2336502

Jenison, 2000

Deng, 2011, Investigation of the recurrence patterns of gastric cancer following a curative resection, Surg Today, 41, 210, 10.1007/s00595-009-4251-y

Rougier, 2011, Surrogate endpoints for overall survival in resectable gastric cancer and in advanced gastric carcinoma: analysis of individual data from the gastric collaboration, Ann Oncol, 22, v10

Haller, 2011, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J Clin Oncol, 29, 1465, 10.1200/JCO.2010.33.6297

Schmoll, 2007, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients, J Clin Oncol, 25, 102, 10.1200/JCO.2006.08.1075

Strong, 2010, Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram, Ann Surg, 251, 640, 10.1097/SLA.0b013e3181d3d29b

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X